Suven Life Sciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+6.9%−43.1%−13.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−71.6%−29.5%−1.7%
−69.1%−27.6%−1.6%
−71.9%−53.0%+11.2%
−64.6%−52.9%+27.3%
+361.8%−52.6%−26.7%
+437.7%−59.3%−28.1%
−95.8%−86.5%+60.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹6,967 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-13.6-43.1+6.9—
EBITDA Growth—-1.7-29.5-71.6—
EBIT Growth—-1.6-27.6-69.1—
Net Income Growth—+11.2-53.0-71.9—
EPS Growth—+27.3-52.9-64.6—
Total Assets Growth—-26.7-52.6+361.8—
Total Equity Growth—-28.1-59.3+437.7—
Cash from Operations Growth—+60.3-86.5-95.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.